Connect with us

Hi, what are you looking for?


JPMorgan sees another 20% upside in Regeneron shares: this is why

buy regeneron stock jpmorgan analyst

Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have already gained about 25% since early September but a JPMorgan analyst is convinced the stock will continue to move up in the coming months.

Regeneron shares could climb further to $850

Chris Schott recommends that investors buy Regeneron shares as they have upside to $850. That price objective translates to another 20% gain from here.

The analyst expects Regeneron Pharmaceuticals’ Eylea drug for age-related macular degeneration to fuel the next leg up in its stock price.

While we expect Eylea trends to be in focus given this quarter’s volatility and Vabysmo launch in 2022, we see these concerns as short-term and expect the launch of high-dose Eylea to represent a far more important driver for REGN shares.

He’s bullish even though Eylea sales were down 3.0% year-on-year in the fourth quarter of 2022.

What other catalysts could help Regeneron shares?

Schott agrees that Eczema is a crowded market but still expects Regeneron’s Dupixent to also help unlock more upside for its share price moving forward. His note reads:

We see Dupixent as well-positioned for further volume gains with a dominant share in one of the least penetrated major immunology categories.

That therapy, the analyst added, will help the company expand biologic penetration in atopic dermatitis by over 100% in the next five years.

Initial data for the company’s prostate cancer treatment looks promising as well, Schott concluded. At about 15 times, Regeneron shares are trading at a discount to their average price-to-earnings multiple over the past five years.

The post JPMorgan sees another 20% upside in Regeneron shares: this is why appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Mimiq, Inc is announcing today the launch of their new product, Mimiq Track, at CES as part of their latest product line to operate...


    Bayerische Motoren Werke AG (ETR: BMW) shares have advanced more than 15% since the beginning of October 2022, and the current share price stands...

    Editor's Pick

    In Risky Business: Why Insurance Markets Fail and What to Do About It (Yale University Press, 2023), economists Liran Einav (Stanford), Amy Finkelstein (MIT),...

    Editor's Pick

    Real gross domestic product rose at a revised 3.2 percent annualized rate in the third quarter versus a 0.6 percent rate of decline in...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023